logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
E

Ewa Kalinka-Warzocha

polish mother's memorial hospital research institute
H指数:28
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab

贝伐珠单抗治疗晚期卵巢癌患者中，初次减瘤术与间隔减瘤术的实世界疗效比较：一项多中心队列研究

Cancers
IF4.4
2026-03-020
OAAI
Kaja Michalczyk; Lubomir Bodnar; Marta Czeluścińska-Murawiec; Anna Dańska-Bidzińska; Paweł Derlatka; Beata Maćkowiak-Matejczyk; Wioleta Sawczuk; Barbara Radecka; Edyta Operacz; Szymon Piątek; Ewa Kalinka; Adam Miller; Anita Chudecka-Głaz
REAL-WORLD OUTCOMES WITH PALBOCICLIB, RIBOCICLIB, AND ABEMACICLIB PLUS ENDOCRINE THERAPY IN HR+/HER2− ADVANCED BREAST CANCER: A MULTICENTER RETROSPECTIVE STUDY

真实世界研究中，PALBOCICLIB、RIBOCICLIB和ABEMACICLIB联合内分泌疗法在HR+/HER2−晚期乳腺癌中的疗效：一项多中心回顾性研究

The Breast
IF0
2025-11-240
OAAI
Renata Duchnowska; Katarzyna Soter; Katarzyna Pogoda; Jolanta Smok-Kalwat; Aleksandra Grela-Wojewoda; Karolina Winsko-Szczęsnowicz; Agnieszka Kowalewska-Felczak; Marek Szwiec; Iwona Danielewicz; Joanna Streb; Tomasz Lewandowski; Bartosz Szymanowski; Joanna Kiszka; Barbara Radecka; Ewa Kalinka; Bartosz K. Sobocki; Maria Litwiniuk; Aleksandra Łacko; Anna Bałata; Justyna Żubrowska
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Xevinapant联合avelumab治疗晚期实体瘤，并在晚期非小细胞肺癌中进行剂量扩展：一项开放标签、非随机 Ib 期研究的探索性生物标志物、安全性和有效性分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-05-080
OA
Glenwood Goss; Tudor Ciuleanu; Rodryg Ramlau; Daniel J. Renouf; Quincy Chu; Ewa Kalinka; Piotr Sawrycki; Jonathan Bramson; Brad H. Nelson; Rafael Crabbé; Eric LaCasse; Bryan Lo; Daniela A. Sahlender; Philippa Crompton; Franck Brichory; Luke Piggott; Michael Schenker; Rosalyn Juergens
BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin plus etoposide plus nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

BMS-986012（抗岩藻糖基单唾液酸神经节苷脂-1[fuc-GM1]）联合卡铂、依托泊苷和纳武利尤单抗（CE/NIVO）作为广泛期小细胞肺癌（ES-SCLC）的一线（1L）疗法：一项随机Ⅱ期研究的期中分析（IA）

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Kalinka, E.; Bahce, I.; Navarro Mendivil, A. F.; Ready, N.; Chu, Q. S-C.; Sugawara, S.; Sibille, A.; Provencio Pulla, M.; Johnson, M. L.; Hiltermann, J. T. J. N.; Ciuleanu, T-E.; Dziadziuszko, R.; Santo, A.; Zhang, Y.; Liu, Y.; Sarmiento, R.; Tannenbaum-Dvir, S.; Ojalvo, L.; Wu, J.; O'Byrne, K. J.
Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice
FRONTIERS IN ONCOLOGY
IF3.3
2024-01-230
OAAI
Knetki-Wroblewska, Magdalena; Dziadziuszko, Rafal; Jankowski, Tomasz; Krawczyk, Pawel; Bryl, Maciej; Stencel, Katarzyna; Wrona, Anna; Bandura, Artur; Smok-Kalwat, Jolanta; Rok-Knapinska, Jolanta; Szydziak-Zwierzynska, Kinga; Rogoziewicz, Krzysztof; Czyzewicz, Grzegorz; Wojtowicz, Monika; Wojtukiewicz, Marek; Kalinka, Ewa; Wysocki, Piotr J.; Lobacz, Mateusz; Milanowski, Janusz; Pawlik, Hubert; Kowalski, Dariusz M.; Krzakowski, Maciej
Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-0110
PRE
Janne, Pasi A.; Bigot, Frederic; Papadopoulos, Kyriakos; Eberst, Lauriane; Sommerhalder, David; Lebellec, Loic; Voon, Pei Jye; Pellini, Bruna; Kalinka, Ewa; Arbour, Kathryn; Herzberg, Benjamin; Boni, Valentina; Bordenave, Stephanie; Lee, Hyun Woo; Ou, Sai I.; Riess, Jonathan Wesley; Beck, Joseph T.; Ponz-Sarvise, Mariano; Ascierto, Paolo Antonio; Choi, Yoon Ji; Yang, Michelle; Bao, Lei; Raman, Rakesh; Yang, Luxi; Mu, Yunming; Wong, Sofia; Dua, Richa; Johnson, Melissa
Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OAAI
Carcereny, E.; Felip, E.; Majem, M.; Doger de Speville, B.; Clay, T. D.; Bondarenko, I.; Peguero, J.; Dols, M. Cobo; Forster, M. D.; Ursol, G.; Kalinka, E.; Garcia Ledo, G. M.; Vila Martinez, L.; Iams, W.; Krebs, M. G.; Kefas, J.; Efthymiadis, K.; Perera, S.; Mueller, C.; Triebel, F.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3

cemiplimab加化疗一线治疗晚期非小细胞肺癌的生活质量: 3期EMPOWER-lung 3患者报告的结果

CANCER
IF5.1
2023-05-085
OAAI
Makharadze, Tamta; Quek, Ruben G. W.; Melkadze, Tamar; Gogishvili, Miranda; Ivanescu, Cristina; Giorgadze, Davit; Dvorkin, Mikhail; Penkov, Konstantin; Laktionov, Konstantin; Nemsadze, Gia; Nechaeva, Marina; Rozhkova, Irina; Kalinka, Ewa; Gessner, Christian; Moreno-Jaime, Brizio; Passalacqua, Rodolfo; Konidaris, Gerasimos; Rietschel, Petra; Gullo, Giuseppe
Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses
CANCER RESEARCH
IF16.6
2023-04-140
PRE
Chu, Quincy; Ciuleanu, Tudor; Ramlau, Rodryg; Renouf, Daniel; Juergens, Rosalyn; Kalinka, Ewa; Sawrycki, Piotr; Bramson, Jonathan; Nelson, Brad; Crabbe, Rafael; Sahlender, Daniela A.; Crompton, Philippa; Rouits, Elisabeth; Spaggiari, Dany; Brichory, Franck; Piggott, Luke; Schenker, Mike; Goss, Glenwood
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
NATURE MEDICINE
IF50
2022-08-25127
OAAI
Gogishvili, Miranda; Melkadze, Tamar; Makharadze, Tamta; Giorgadze, Davit; Dvorkin, Mikhail; Penkov, Konstantin; Laktionov, Konstantin; Nemsadze, Gia; Nechaeva, Marina; Rozhkova, Irina; Kalinka, Ewa; Gessner, Christian; Moreno-Jaime, Brizio; Passalacqua, Rodolfo; Li, Siyu; McGuire, Kristina; Kaul, Manika; Paccaly, Anne; Quek, Ruben G. W.; Gao, Bo; Seebach, Frank; Weinreich, David M.; Yancopoulos, George D.; Lowy, Israel; Gullo, Giuseppe; Rietschel, Petra
Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial
ANNALS OF ONCOLOGY
IF65.4
2021-12-011
OA
Makharadze, T.; Quek, R. G.; Melkadze, T.; Gogishvili, M.; Ivanescu, C.; Giorgadze, D.; Dvorkin, M.; Penkov, K.; Laktionov, K.; Nemsadze, G.; Nechaeva, M.; Rozhkova, I.; Kalinka, E.; Gessner, C.; Moreno-Jaime, B.; Passalacqua, R.; Konidaris, G.; Rietschel, P.; Gullo, G.
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
TARGETED ONCOLOGY
IF4
2021-04-0713
OAAI
Bjartell, Anders; Lumen, Nicolaas; Maroto, Pablo; Paiss, Thomas; Gomez-Veiga, Francisco; Birtle, Alison; Kramer, Gero; Kalinka, Ewa; Spaeth, Dominique; Feyerabend, Susan; Matveev, Vsevolod; Lefresne, Florence; Lukac, Martin; Wapenaar, Robert; Costa, Luis; Chowdhury, Simon
PROGRESSION-FREE SURVIVAL AND BIOMARKER CORRELATES OF RESPONSE WITH BEMPEG PLUS NIVO IN PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC MELANOMA: RESULTS FROM THE PIVOT-02 STUDY
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2020-12-105
PREAI
Diab, Adi; Tykodi, Scott; Daniels, Gregory; Maio, Michele; Curti, Brendan; Lewis, Karl; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander; Cho, Daniel; Guan, Shanhong; Puente, Erika; Hoch, Ute; Currie, Sue; Nguyen, Tuan; Lin, Wei; Tagliaferri, Mary; Zalevsky, Jonathan; Sznol, Mario; Hurwitz, Michael
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in Poland: analysis of patient series and practical guidelines for breast surgeons
ARCHIVES OF MEDICAL SCIENCE
IF3.3
2020-11-050
OAAI
Pluta, Piotr; Giza, Agnieszka; Kolenda, Malgorzata; Fendler, Wojciech; Braun, Marcin; Chudobinski, Cezary; Chalubinska-Fendler, Justyna; Araszkiewicz, Michal; Loga, Karolina; Lembas, Lubomir; Witkowska, Magdalena; Pluta, Agnieszka; Kolasinski, Jerzy; Basta, Pawel; Kolacinska-Voytkuv, Agnieszka; Ciesla, Slawomir; Jesionek-Kupnicka, Dorota; Jankau, Jerzy; Kuczynski, Maciej; Kalinka, Ewa; Zadrozny, Marek; Murawa, Dawid

研究方向

暂未获取到该数据
P
Paweł Krawczyk
H 指数:28论文数:292被引数:2,701
J
Janusz Milanowski
H 指数:32论文数:366被引数:4,832
N
Nicolaas Lumen
H 指数:44论文数:396被引数:8,575
R
Rodryg Ramlau
H 指数:53论文数:381被引数:2.3万
K
Krzysztof Warzocha
H 指数:37论文数:440被引数:6,813
R
Rodolfo Passalacqua
H 指数:39论文数:277被引数:1.1万
R
Robert Wapenaar
H 指数:12论文数:57被引数:712
T
Thomas Paiss
H 指数:24论文数:109被引数:2,535
A
Anders Bjartell
H 指数:81论文数:714被引数:2.3万
R
Renata Duchnowska
H 指数:21论文数:218被引数:2,013